title: Increased expression of glycoprotein 340 in the ethmoid sinus mucosa of patients with chronic sinusitis.
abstract: OBJECTIVE
  To investigate the expression and distribution of glycoprotein 340 (gp340), a secretory glycoprotein, in normal human sinus mucosa and inflammatory sinus mucosa and evaluate the possible effects of gp340 on the development of chronic sinusitis. Glycoprotein 340 was identified as a key element in the innate host defense mechanism on many mucosal surfaces and is directly involved in defense functions aimed at clearing gram-positive and gram-negative bacteria.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Tertiary academic institution.
  
  
  METHODS
  Normal sinus mucosa was obtained from the ethmoid sinus mucosa of 8 patients with blowout fractures undergoing endoscopic reduction. Inflammatory sinus mucosa was taken from 25 patients with chronic polypoid sinusitis during endoscopic sinus surgery.
  
  
  METHODS
  Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemical analysis, and Western blotting were performed.
  
  
  METHODS
  The expression level and distributional pattern of gp340 in normal and inflammatory sinus mucosa were analyzed.
  
  
  RESULTS
  Transcripts of the gp340 gene were detected in all human sinus tissues analyzed by RT-PCR. Immunohistochemical analysis revealed that gp340 is mainly localized in submucosal gland of both normal and inflammatory sinus mucosa. Semiquantitative RT-PCR and Western blot analysis showed the increased expression levels of gp340 in the inflammatory sinus mucosa compared with the normal sinus mucosa.
  
  
  CONCLUSIONS
  These results suggest that gp340 may play a constitutive role in nasal defense and may be up-regulated in response to inflammation, participating in antimicrobial defense in chronic sinusitis.
authors.affiliation: Department of Otorhinolaryngology-Head & Neck Surgery, College of Medicine, Korea University, 126-1 5 Ka Anam-Dong, SungBuk-Ku, Seoul, South Korea.
authors.forename: Tae Hoon
authors.initials: TH
authors.lastname: Kim
authors.forename: Sang Hag
authors.initials: SH
authors.lastname: Lee
authors.forename: Heung Man
authors.initials: HM
authors.lastname: Lee
authors.forename: Hak Hyun
authors.initials: HH
authors.lastname: Jung
authors.forename: Seung Hoon
authors.initials: SH
authors.lastname: Lee
authors.forename: Woo Sung
authors.initials: WS
authors.lastname: Cho
authors.forename: Young Gi
authors.initials: YG
authors.lastname: Cinn
authors.forename: Hwan
authors.initials: H
authors.lastname: Choe
authors.forename: Moo Pil
authors.initials: MP
authors.lastname: Kim
authors.forename: Ik One
authors.initials: IO
authors.lastname: Yoo
authors.forename: Ho Yeon
authors.initials: HY
authors.lastname: Hwang
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002908:Chronic Disease; D005005:Ethmoid Sinus / Q000378:metabolism*; D005260:Female; D006801:Humans; D018928:Immunity, Mucosal / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009297:Nasal Mucosa / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D011971:Receptors, Immunologic / Q000235:genetics / Q000378:metabolism*; D012852:Sinusitis / Q000209:etiology / Q000378:metabolism* / Q000473:pathology
chemical_list: D012333:RNA, Messenger; D011971:Receptors, Immunologic; C116303:glycoprotein 340